Biodata company CytoReason has used artificial intelligence (AI) to predict whether patients will respond to tumour necrosis factor (TNF) alpha drugs. Using an AI model of the immune system, the Tel Aviv-based company used information from three clinical trials to study the RNA from lesion tissue samples from patients that responded and those that did not respond to anti-inflammatory drugs such...